Statement: Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients. cdisc adas-cog - delayed word recall: word 5 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 5.
Primary_evidence: Outcome Measurement:    Severity of Adverse Events   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.   Time frame: From cycle 1 up to approximately 3 years Results 1:    Arm/Group Title: Trastuzumab Emtansine   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks.   Overall Number of Participants Analyzed: 70   Measure Type: Count of Participants   Unit of Measure: Participants  Grade 1: 53  75.7%   Grade 2: 40  57.1%   Grade 3: 18  25.7%   Grade 4: 2   2.9%   Grade 5: 12  17.1%